Healthcare Business Review: Pfizer’s Continuing Legal Defense, Sarepta’s Good News

Nektar Therapeutics (NASDAQ:NKTR) reports that a Phase 1a clinical study of its drug candidate NKTR-192, which is a short-acting mu-opioid analgesic for the treatment of acute pain, met its target pharmacokinetic profile. Additionally, dosing has begun in a second Phase 1a clinical study that will explore the pharmacodynamic profile of the drug administered to healthy subjects.

Pfizer Inc. (NYSE:PFE) will continue to defend itself ‘vigorously’, as United States District Judge Sullivan in Manhattan grants class-action status to former Wyeth investors who accused a Pfizer division of misleading them regarding risks associated with Pristiq, an antidepressant, according to Reuters.

Don’t Miss: Are Staph Infection Vaccines on the Cusp?

A bad day for Medtronic Inc. (NYSE:MDT), as an appeals court overturns a decision that the firm did not infringe on Boston Scientific Corporation (NYSE:BSX) CRT patents, and thus has remanded the case for further proceedings. According to the appeals court, the lower court was at fault for relying upon a “legally incorrect allocation of the burden of proof” along with incorrectly construing the claim terms in the suit.

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) jumped on the news that the FDA has granted Fast Track approval status for its lead drug candidates, AVI-7288 and AVI-7537, for the treatment of Ebola and Marburg viruses respectively. The two drugs are being developed under a United States Department of Defense contract.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

More from The Cheat Sheet